Semaglutide Use in Elderly Obese Patients

NCT ID: NCT05302596

Last Updated: 2025-04-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2024-10-30

Brief Summary

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Detailed Description

This will be a single center, prospective, open label, randomized and controlled pilot study to investigate the effects of semaglutide addition to a standard weight loss intervention program for 16 weeks on body weight and composition, adipose tissue metabolism and muscle strength compared to the standard weight loss program alone in elderly obese patients.

Eligible and qualified patients will be randomized 1:1 in pairs (8 pairs) matched by age and BMI within 5% and by gender to one of two open-label interventions. Priority of enrollment will be to match already existing and non-matched pair(s) before starting new ones. However, participants will not need to wait until they are matched to be enrolled in the study. The two open-label interventions are:

1. Control group: Standard of care weight loss program that includes lifestyle changes and personalized exercise and dietary education.

2. Semaglutide group: semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose. Patients will be instructed on how to inject themselves with the drug and how to increase the dose. During dose escalation, we will be monitoring the subject more extensively (4 weeks and 8 weeks), compared to clinical practice, for any side effects including if they experience any GI side effects, and subjects will be kept at the maximum tolerable dose up to 1mg/week.

At the baseline visit, and for all other visits, patients will come fasting (10 -12 hours) to the research center. Patients will visit the research center at 4 weeks (safety visit), 8 weeks and at 16 weeks (final study assessment visit). Blood (about 25 ml), body weight and other vitals, adverse events including hypoglycemia (blood sugar <70 mg/dl) will be collected at all visits. Fat biopsy aspiration, DEXA scans, muscle strength measurement and age-appropriate quality of life questionnaire (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) will be performed at 0- and 16-weeks visits.

All patients will receive instructions at the beginning of the study on weight loss nutritional program and appropriate physical activity to be performed for the next 16 weeks. The program will be based, in-part, on dietary and exercise habits collected at screening visit. For the entire duration of the study, participants will maintain a daily diary to document food and exercise activities to ensure compliance with lifestyle program provided. At the 4- and 8-weeks visits, the daily diary will be reviewed for food and exercise activities, and instructions will be provided again to reinforce intervention.

Patients will be provided with glucose meter and glucose strips to measure fingerpick blood glucose. For the entire duration of the study, patients will be asked to measure their blood sugars at least one time after exercise and to record any hypoglycemic events (glucose <70mg/dl) in their diary, Patients will be instructed to record any other untoward side effects like nausea, vomiting, changes in appetite and other experiences in the diary. Patients will be instructed to call the Diabetes Center to speak to a study investigator directly in case of any problem or untoward side effects.

they have a question or side effects.

Standard of care weight loss program:

All patients will be instructed to implement dietary and exercise program for the next 16 weeks and to record their activities on daily food and exercise diary provided.

1. Energy intake should be reduced by 500-750kcal/day.

2. Dietary fat should be reduced to 30% of total energy intake maximally.

3. Meal replacements (if used) will be consumed during breakfast and lunch.

4. Dinner consisted of conventional food and participants will be encouraged to eat fruits and vegetables within their calorie limit.

5. Participants should ingest 1.0-1.5g of protein/kg/day and spread consumption equally throughout the day. A leucine-enriched balanced amino acid supplement can be used.

6. Subjects will be instructed to perform aerobic, muscle-strengthening, flexibility, and balance exercises. Minimally, this should include moderate-intensity aerobic activity for 30 minutes five days per week or vigorous-intensity aerobic activity for 20 minutes three days a week, 10-15 repetitions of 8-10 major muscle group strengthening exercises two or more nonconsecutive days each week, 10 minutes of flexibility activities at least two days a week, and balance exercises three times a week for fall prevention.

Conditions

Obesity; Aging

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Semaglutide

Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks.

Group Type: EXPERIMENTAL

Semaglutide Pen Injector

Intervention Type: DRUG

semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention

standard of care only

Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise)

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Semaglutide Pen Injector

semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention

Intervention Type: DRUG

Other Intervention Names

Ozempic

Eligibility Criteria

Inclusion Criteria

1. Males and females age: ≥65 years

2. BMI ≥30 Kg/m2 AND waist circumference for women: > 80 cm and for men: > 90 cm

3. Stable body weight (no more than ±3 kg change during the 3 months prior to screening)

4. Able to participate in personalized physical activities and dietary instructions.

5. Participant must be able to read, write, and understand the English language and be able to provide written consent.

Exclusion Criteria

1. Current diagnosis of weight changing condition including cancer, gastrointestinal conditions or eating disorders

2. GLP-1R agonists use within last 6 months

3. Diagnosis of type 1 or 2 diabetes

4. Impaired cognitive function (VA-St. Louis University Mental Survey (VA-SLUMS) score ≤ 19)

5. History of chronic/idiopathic acute pancreatitis

6. Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

7. Previous surgical treatment for obesity

8. Smoking or use of any nicotine products

9. Use of any medication that could interfere with trial results especially weight management drugs

10. Anticipated change in lifestyle (e.g., dietary, exercise or sleeping pattern) other than provided by the study.

11. Hepatic disease or cirrhosis

12. Aspartate Aminotransferase (AST) > 3X Upper limit of normal (ULN) and/or Alanine aminotransferase (ALT) > 3X ULN

13. Inability to give informed consent

14. History of gastroparesis

15. History of serious hypersensitivity reaction to these agents

16. Alcoholism

17. Patients with retinopathy

18. Participation in any other concurrent interventional clinical trial -

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Center for Advancing Translational Sciences (NCATS)

NIH

Sponsor Role: collaborator

State University of New York at Buffalo

OTHER

Sponsor Role: lead

Responsible Party

Husam A Ghanim

Research Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Husam A Ghanim, PhD

Role: PRINCIPAL_INVESTIGATOR

State University of NY at Buffalo

Locations

Diabetes and Endocrinology Research Center

Buffalo, New York, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

UL1TR001412

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY00005760

Identifier Type: -

Identifier Source: org_study_id